Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Sep 27, 2024
Open Peer Review Period: Oct 1, 2024 - Nov 26, 2024
Date Accepted: Mar 18, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Reflections on the Optimal Use of eDiaries for Data Collection in Vaccine Clinical Trials
ABSTRACT
Recent years have witnessed a transformative shift in the way patient-reported outcomes are captured. The increasing adoption of digital health technologies offers exciting possibilities for more efficient, engaging, and insightful electronic data collection. Electronic diaries (eDiaries) represent a paramount resource that could improve data quality, reduce costs, and limit the burden on clinical staff and trial participants. Herein, we present our perspective on how to effectively use eDiaries to optimize the data collection processes in vaccine clinical trials. We begin with with a brief description of the benefits of eDiaries in vaccine clinical trials and provide reflections on key measures such as programming the eDiary platform, training the trial staff and participants, and real-time monitoring of participant compliance, which are crucial for leveraging eDiaries for optimal data collection. By implementing the measures discussed in this paper, eDiaries can offer significant advantages for both trial participants and clinical investigators by ensuring quality and integrity of the data collected.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.